Appl. No.

: 10/662,002

**Filed** 

September 12, 2003

## AMENDMENTS TO THE CLAIMS

## Please amend the claims as follows:

:

- 1. (Currently amended) A therapeutic composition for topical application, consisting essentially of:
  - a sphingolipid long-chain base present at from about 0.01 to 5.0% and lysophosphatidic acid present at from about 0.001 to 1.0%,

wherein the shingolipid sphingolipid long-chain base is one or more selected from the group consisting of phytoshingosine—phytosphingosine, acetylphytosphingosine, tetraacetyl phytosphingosine, hexanoylphytoshingosine—hexanoylphytosphingosine and acetylphytosphingosine phosphate.

- 2. Cancelled
- 3. Cancelled
- 4. Cancelled
- 5. (Currently amended) A therapeutic composition for topical application, consisting essentially of:

30 to 90% by weight of a substrate or a carrier for skin application;

0.01 to 5.0% by weight sphingolipid long-chain base;

0.001 to 1.0% by weight lysophosphatidic acid;

and 1.0 to 40% by weight of organic or inorganic additives, wherein the shingolipid\_sphingolipid\_long-chain base is one or more selected from the group consisting of phytoshingosine—phytosphingosine, acetylphytosphingosine, tetraacetyl phytosphingosine, hexanoylphytoshingosine—hexanoylphytosphingosine and acetylphytosphingosine phosphate.

- 6. (Original) The therapeutic composition according to claim 5, wherein the organic additives contain ceramide, cholesterol and fatty acid.
- 7. (Original) The therapeutic composition according to claim 6, wherein the organic additives contain a weight ratio of ceramide: cholesterol: fatty acid of from about 40 to 60 %: from about 20 to 30 %: from about 20 to 30 %.
- 8. (Original) The therapeutic composition according to claim 5, wherein the ceramide comprises one or more selected from the group consisting of: ceramide 3 ceramide 6,

Appl. No. : 10/662,002

Filed: September 12, 2003

and a mixture thereof, and wherein the ceramide has the same stereochemical composition as the ceramide in human skin lipids.

9. (Original) The therapeutic composition according to claim 1, wherein the lysophosphatidic acid is one or more selected from the group consisting of lyso-stearoyl phosphatidic acid (18:0), lyso-oleoyl phosphatidic acid (18:1), lyso-palmitoyl phosphatidic acid (16:0) and natural lyso-phosphatidic acid derived from egg yolk or beans.

- 10. Cancelled
- 11. Cancelled
- 12. **(Original)** The therapeutic composition according to claim 1, wherein the composition is formulated into a form selected from the group consisting of: a cream, a lotion, an ointment, a skin toner, an essence, a body wash, and a shampoo.